Table of Contents
PPT Slide
PPT Slide
Choice of Endpoints (Cont.)
HIV RNA Endpoints
CrossSectional vs. Failure Over Time
Time to Failure vs. Cumulative Proportion
PPT Slide
PPT Slide
Purely Virologic vs. Composite
Issues in Definition of:
Clinical Beliefs Underlying the Appropriate Use of Each Endpoint
Types of Study Endpoint in HIV Disease Studies
Composite Endpoints
Example
Example Continued
ACTG 359:Proportion vs. Change
ACTG 359: Proportion Below Detection
ACTG 359: Proportion Below Detection
ACTG 359: Proportion Below Detection
ACTG 359: Mean HIV1 RNA Change from Baseline
Data Completeness
Primary Efficacy Comparison
Secondary Efficacy Analysis: RNA Change
ACTG 364
ACTG 364
ACTG 364
Loss to FollowUp
PPT Slide
PPT Slide
PPT Slide
ACTG 398
ACTG 398 Continued
ACTG 398
ACTG 398 Continued
ACTG 398 Continued
ACTG 398 Continued
Analysis of Quantitative Endpoints
PPT Slide
PPT Slide
PPT Slide
